This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmutte, C. Articles by Fishel, R. Search for Related Content PubMed PubMed Citation Articles by Schmutte, C. Articles by Fishel, R.

Characterization of the Human Rad51 Genomic Locus and Examination of Tumors with 15q14–15 Loss of Heterozygosity (LOH)¹

Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 [C. S., G. T., M. M. S., R. F.]; Universitäts-Frauenklinik, Universität Bonn, 53105 Bonn, Germany [K. R., R. S.]; and Universitätsklinikum Charité, Humboldt-Universität, Institut für Neuropathologie, D-13353 Berlin, Germany [A. v. D.]

Human Rad51 (hRad51) has been found to be associated with BRCA1, BRCA2, and p53 either directly or indirectly and is one of at least eight human genes that are members of the Escherichia coli RecA/Saccharomyces cerevisiae Rad51 family thought to affect genomic stability through DNA recombination/repair processes. While inactivation of DNA mismatch repair clearly leads to instability of repeated sequences and to an increased risk for tumorigenesis, such a parallel for the RecA family members has not been reported. Recently, a high frequency of loss of heterozygosity at chromosome 15q14–15, near the genomic region containing hRad51, has been reported in human tumors (W. Wick et al., Oncogene, 12: 973–978, 1996). To determine whether hRad51 inactivation may be involved in the etiology of these tumors, we have characterized the hRad51 genetic locus and mapped it to chromosome 15q14–15 within the central region of loss of heterozygosity. However, single-strand conformational polymorphism analysis and direct sequencing of tumors did not reveal any mutations in the hRad51 coding sequence or intron/exon boundaries. We also examined the DNA methylation status of a CpG-rich region in the putative hRad51 promoter region. No indication of hypermethylation was found. These results suggest that hRad51 is not a tumor suppressor because it is either an essential gene, redundant gene and/or independent of the BRCA1/BRCA2 tumor suppressor pathway(s).

This article has been cited by other articles:

				C. M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy PNAS, December 30, 2008; 105(52): 20810 - 20815. [Abstract] [Full Text] [PDF]

				V. Labi, M. Erlacher, S. Kiessling, C. Manzl, A. Frenzel, L. O'Reilly, A. Strasser, and A. Villunger Loss of the BH3-only protein Bmf impairs B cell homeostasis and accelerates {gamma} irradiation-induced thymic lymphoma development J. Exp. Med., March 17, 2008; 205(3): 641 - 655. [Abstract] [Full Text] [PDF]

				M. Bredel, C. Bredel, D. Juric, G. R. Harsh, H. Vogel, L. D. Recht, and B. I. Sikic High-Resolution Genome-Wide Mapping of Genetic Alterations in Human Glial Brain Tumors Cancer Res., May 15, 2005; 65(10): 4088 - 4096. [Abstract] [Full Text] [PDF]

				R. Natrajan, J. Louhelainen, S. Williams, J. Laye, and M. A. Knowles High-Resolution Deletion Mapping of 15q13.2-q21.1 in Transitional Cell Carcinoma of the Bladder Cancer Res., November 15, 2003; 63(22): 7657 - 7662. [Abstract] [Full Text] [PDF]

				H. W. Mohrenweiser, T. Xi, J. Vazquez-Matias, and I. M. Jones Identification of 127Amino Acid Substitution Variants in Screening 37 DNA Repair Genes in Humans Cancer Epidemiol. Biomarkers Prev., October 1, 2002; 11(10): 1054 - 1064. [Abstract] [Full Text] [PDF]

				E. Raderschall, K. Stout, S. Freier, V. Suckow, S. Schweiger, and T. Haaf Elevated Levels of Rad51 Recombination Protein in Tumor Cells Cancer Res., January 1, 2002; 62(1): 219 - 225. [Abstract] [Full Text] [PDF]